Thrombin Market to Exhibit CAGR of 4.1% Despite Limited Product Innovations | Fortune Business Insights

The Global Thrombin Market was valued at US$ 535.0 Mn and the forecasted CAGR means that this market will be valued at around US$ 738.7 Mn by the end of 2025. . Thrombin inhibitors play a major part in delaying blood clotting.

Pune, India - May 16, 2019 /MarketersMedia/ —

The Global Thrombin Market is favored by the rising incidence of thrombosis among people, globally. The fatal nature of thrombosis and use of thrombin to trump thrombosis is emphasized in Fortune Business Insights’ latest report, titled “Thrombin Market: Global Analysis, Insights and Forecasts, 2019-2026.” In the report, Fortune Business Insights has briefed that an increasing emphasis on clinical trials of thrombin has boosted the global market and it is estimated to expand at a CAGR of 4.1%. As of 2018, the global thrombin market was valued at US$ 535.0 Mn and the forecasted CAGR means that this market will be valued at around US$ 738.7 Mn by the end of 2025.

Thrombosis can be caused due to mere sedentary lifestyle habits such as smoking and some other factors such as heart failures, aging, and cancer. Thrombin inhibitors play a major part in delaying blood clotting. The healing properties of thrombin, along with its ability to minimize bleeding during surgical procedures has led to an increase in demand for thrombin over the years.

Request Sample Copy at https://www.fortunebusinessinsights.com/enquiry/sample/thrombin-market-100170

Widespread Applications of Thrombin to Boost Global Market

Thrombin has come a long way from its conventional use to stop bleeding in small cuts on body parts. Now, thrombin plays a major role in most of the surgeries, worldwide. The clinical efficiency of thrombin has led to its widespread use in the healthcare industry, a key factor enabling growth in the global thrombin market. Thrombin is vastly effective in facilitating surgical hemostasis. Over the years, human thrombin was replaced with bovine thrombin, due to its increased efficiency in surgical procedures.

Bovine-derived thrombin was successfully used in patients with hemodialysis. Bovine thrombin is massively helpful in treating hemorrhages in hemodialysis, wherein an excessive amount of blood is lost. The extent of blood losses in hemodialysis can lead to various disorders and may also prove fatal in some cases. Thus, bovine-derived thrombin is given huge emphasis and healthcare professionals have prioritized thrombin for treating hemorrhages. The thrombin market is therefore forecast to witness a high demand for bovine-derived thrombin in the com9ing years.

Recothrom to Emerge as The Most Widely Used Product Type

As surgical blood loss has been prioritized by surgeons and healthcare professionals worldwide, there is an increasing need for an efficient solution to minimize such severe losses. Recothrom was initially manufactured by a US-based company, ZymoGenetics. After involvement from Bayer Healthcare, Recothrom was later acquired by Baxter International. The 2018 acquisition of Recothrom by Baxter has proved fruitful to the overall market. As of now, Recothrom is the only drug that has been clinically approved for commercial use as a recombinant thrombin brand. Furthermore, Recothrom finds applications in cases where standard surgical procedures such as suture or cautery are ineffective.

Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/thrombin-market-100170

Besides Baxter, there have been significant activities from other companies that have contributed to the growth of the global thrombin market. Attractive business strategies of companies such as Pfizer have had a positive impact on the overall market. Pfizer’s has emerged as the leading company, backed by high clinical efficiency of its product ‘Thrombin JMI’. Some other companies that are operating in the global thrombin market are Johnson & Johnson Services Inc., Shanghai RAAS Blood Products Co. Ltd., Japan Blood Products Organization, and Mochida Pharmaceutical Co.

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Info:
Name: Fortune Business Insights
Email: Send Email
Organization: Fortune Business Insights
Address: Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India
Phone: +1 424 253 0390
Website: https://www.fortunebusinessinsights.com

Source URL: https://marketersmedia.com/thrombin-market-to-exhibit-cagr-of-41-despite-limited-product-innovations-fortune-business-insights/513505

Source: MarketersMedia

Release ID: 513505

More News From Biz Daily Online

Asian stocks gain after US, China announce truce on tariffs

Jun 7, 2020

BEIJING — Asian stock markets have risen after Washington and Beijing announced a truce on tariff hikes in a trade war. Benchmarks in Shanghai, Hong Kong and Seoul advanced. Japanese markets were closed for a holiday. President Donald Trump agreed Friday to put off planned tariff hikes this week on Chinese goods in a fight over Beijing's trade surplus and technology plans. In exchange, he said China would buy American farm goods. But the two sides reported no progress on basic disputes that sparked the 15-month-old fight that threatens global economic growth. Friday's truce "has simply temporarily halted the escalation...

Stocks mixed, oil down as markets await news on Saudi plant

Jun 7, 2020

BANGKOK — World shares were mixed on Tuesday and oil prices eased back pending updates on restoring output at a Saudi Aramco oil processing plant damaged by an attack over the weekend. Chinese benchmarks led declines in Asia after the credit ratings agency Moody's downgraded Hong Kong, citing its recent political turmoil. Germany's DAX lost 0.2% to 12,362 after the ZEW index showed a drop in investor confidence in current economic conditions, pointing to the possibility of a brief recession, but sees a pick-up later in the year. The CAC 40 in Paris added 0.1% to 5,607 and the FTSE...

HK stocks surge on withdrawal of law that sparked protests

Jun 7, 2020

BEIJING — Hong Kong stocks surged Wednesday as the government withdrew a proposed extradition law that sparked three months of protests in the Chinese territory. Hong Kong's benchmark Hang Seng index jumped 3.9% on news of plans for the withdrawal, which Chief Executive Carrie Lam confirmed after markets closed. The protests have disrupted travel, adding to pressure from weakening global trade. Elsewhere, benchmarks in London, Frankfurt, Shanghai and Tokyo rose following surprise weakness in U.S. manufacturing as Britain's Parliament fought over plans to leave the European Union. In early trading, London's FTSE 100 gained 0.8% to 7,326.65 and Frankfurt's DAX...

Asian stocks mixed after US, China impose new tariff hikes

Jun 7, 2020

BEIJING — Asian stocks were mixed Monday after Washington and Beijing escalated their trade war with new tariff hikes. Shanghai and South Korea advanced while Tokyo and Hong Kong declined. Markets reacted less strongly to the weekend tariff hikes on billions of dollars of goods than to previous increases. Investors are hoping for progress in talks this month, but analysts warn the fight over trade and technology is unlikely to be quickly resolved. "The short-lived truce will probably provide limited relief," said Zhu Huani of Mizuho Bank in a report. "Businesses have become increasingly uncertain about future prospects, evidenced by...

Global stocks higher ahead of US Fed chairman's speech

Jun 7, 2020

BEIJING — Global stock markets rose Friday after Wall Street declined ahead of a closely watched speech by the U.S. Federal Reserve chairman. Market benchmarks in London, Frankfurt, Shanghai and Tokyo all advanced. Investors are looking to Jerome Powell's speech Friday for signs of direction on interest rates after two regional Fed presidents said they see no need for a change. Investors expect a cut in September, the Fed's second in three months, to shore up U.S. economic growth amid a tariff war with Beijing and weakening global growth. "Markets seem very clearly positioned for some very dovish guidance from...

About Us

Biz Daily Online gives a complete understanding of the world of business to you. Get today’s business news and learn about the trends that are affecting every business here.

Contact us: sales[at]bizdailyonline.com

Subscribe Now!